Jaran Eriksen

Jaran Eriksen

Adjunct Senior Lecturer | Docent
Visiting address: Institutionen för klinisk forskning och utbildning, Södersjukhuset, 11883 Stockholm
Postal address: S1 Klinisk forskning och utbildning, Södersjukhuset, S1 KI SÖS Forskning Infektion venhälsan, 171 77 Stockholm
Part of:

About me

  • I am an infectious diseases physician and clinical pharmacologist currently working at Stockholm South General Hospital, where I devote half of my time to work in our HIV clinic. I am also an Associate professor at Karolinska Institutet, where I am the group leader of the research group "Infektion Venhälsan" at the Department of Clinical Science and Education (KISÖS). In addition, I am affiliated to the Karolinska Institutet Department of Global Public Health (GPH) where I am member of the Health Systems and Policy Research group/Improving Use of Medicines team. I am currently also co-lead of the working group for GlobeLife, an initiative aiming to promote and facilitate global health research and training collaboration between Karolinska Institutet and Uppsala University. I am a member of the Swedish National Reference group for Antiviral Therapy (RAV) and part of the group developing and updating the national guidelines for HIV treatment and prevention.



    Qualifications
    2021: Docent (Associate professor) in Global Health
    2006: PhD Karolinska Institutet: Managing childhood malaria in rural Tanzania
    - focusing on drug use and resistance
    2001: MD Karolinska Institutet

    Clinical specialist certification
    2022 specialist physician in infectious diseases.
    2016 specialist physician in clinical pharmacology.

    Current position
    Specialist physician in infectious diseases, Unit of Infectious
    diseases/Venhälsan, Södersjukhuset, Stockholm, 40% research time

Research

  • My research focuses on different aspects of rational use of medicines, regarding management of infectious diseases common in low-and middle-income countries (LMIC). Within this field my interest spans broadly from behavioural change and policy to pharmacokinetics and resistance mutations. Although my focus is on LMIC, I also work in high-income settings, such as Sweden. I aim to develop models for improving treatment of infectious diseases that can be applied in both low- and high-resource settings. A major part of my work has a health systems approach but also includes clinical trials with pharmacokinetic and pharmacogenetic aspects and how these influence treatment outcome and practices.

Articles

All other publications

Grants

  • Swedish Research Council
    1 January 2026 - 31 December 2028
    In August 2024, multiple viral mpox outbreaks in Africa, uncontrolled spread of new strains, and ongoing global transmission among men who have sex with men (MSM) led WHO to declare a second global mpox emergency (PHEIC). Due to vaccine scarcity, Sweden followed EU recommendations for a dose-sparing intradermal (ID) vaccination regime, using one-fifth (0.1 ml) of the standard (0.5 ml) subcutaneous (SC) dose of the only approved vaccine, MVA-BN. Now, breakthrough infections in primary mpox-vaccinated MSM are rising, also in Sweden. Evidence of waning antibodies and lack of booster studies warrant this randomized clinical trial (RCT).We will conduct a phase 4, low-intervention RCT in 490 MSM who are primary mpox-vaccinated, randomizing them to an ID or SC booster or a control arm. Innovative methods will assess mucosal and serological immune responses (T-cells, binding/neutralizing antibodies) over two years, with noninferiority of ID vs. SC after one month as the primary endpoint. Safety is monitored. The study has regulatory and ethical approval in CTIS. Once funded it is ready to start within Venhälsan’s cohort of &gt
    3800 primary vaccinated MSM at South General Hospital, Stockholm. This study answers pressing public health questions on booster effectiveness, particularly if the ID dose-sparing regime is non-inferior to standard care. Results will guide global recommendations and are urgent, given the need for MVA vaccine stockpiles for bioterror threats amid ongoing scarcity.
  • Swedish Research Council
    1 December 2025 - 30 November 2028
    In August 2024, multiple viral mpox outbreaks in Africa, uncontrolled spread of new strains, and ongoing global transmission among men who have sex with men (MSM) led WHO to declare a second global mpox emergency (PHEIC). Due to vaccine scarcity, Sweden followed EU recommendations for a dose-sparing intradermal (ID) vaccination regime, using one-fifth (0.1 ml) of the standard (0.5 ml) subcutaneous (SC) dose of the only approved vaccine, MVA-BN. Now, breakthrough infections in primary mpox-vaccinated MSM are rising, also in Sweden. Evidence of waning antibodies and lack of booster studies warrant this randomized clinical trial (RCT).We will conduct a phase 3, low-intervention RCT in 490 MSM who are primary mpox-vaccinated, randomizing them to an ID or SC booster or a control arm. Innovative methods will assess mucosal and serological immune responses (T-cells, binding/neutralizing antibodies) over two years, with noninferiority of ID vs. SC after one month as the primary endpoint. Safety is monitored. The study has regulatory and ethical approval in CTIS. Once funded it is ready to start within Venhälsan’s cohort of &gt
    3800 primary vaccinated MSM at South General Hospital, Stockholm. This study answers pressing global health questions on booster effectiveness, particularly if the ID dose-sparing regime is non-inferior to standard care. Results will guide global recommendations and are urgent, given the need for MVA vaccine stockpiles for bioterror threats amid ongoing scarcity.
  • Swedish Research Council
    1 January 2022 - 31 December 2025
  • Swedish Research Council
    1 January 2020 - 31 December 2021
  • Swedish Research Council
    1 January 2014 - 31 December 2016
  • Swedish Research Council
    1 January 2012 - 31 December 2014
  • Swedish Research Council
    1 January 2012 - 31 December 2014
  • Resebidrag: XVII International AIDS Conference, 3-8 Augusti 2008, Mexico City
    Swedish Research Council for Health Working Life and Welfare
    1 July 2008 - 30 September 2008

Employments

  • Adjunct Senior Lecturer, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, 2026-2028
  • Adjunct Senior Lecturer, Department of Global Public Health, Karolinska Institutet, 2025-2028
  • Assistant Professor, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, 2024-2026

Degrees and Education

  • Docent, Karolinska Institutet, 2021
  • Doctor Of Philosophy, Department of Laboratory Medicine, Karolinska Institutet, 2006
  • University Medical Degree, Karolinska Institutet, 2001

News from KI

Events from KI